Welcome to our dedicated page for Omeros SEC filings (Ticker: OMER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omeros Corporation (NASDAQ: OMER) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, together with AI-generated summaries to help interpret key points. Omeros is a biopharmaceutical company developing and commercializing first-in-class therapeutics for complement-mediated diseases, cancers, and addictive or compulsive disorders, and its filings offer detailed insight into these activities.
Through current reports on Form 8-K, Omeros documents material events such as the U.S. FDA approval of YARTEMLEA (narsoplimab-wuug) for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), conference call announcements, quarterly financial results, and shareholder meeting outcomes. Other 8-K filings describe the asset purchase and license agreement with Novo Nordisk for the MASP-3 inhibitor zaltenibart (OMS906), including eligibility for upfront and milestone payments and tiered royalties, as well as registered direct offerings and related purchase and placement agreements.
Investors can use this page to track how Omeros reports on capital structure and liquidity, including secured term loans, convertible senior notes, equity offerings, and royalty arrangements, all as disclosed in its SEC reports. Filings also outline grant funding for programs like OMS527 for cocaine use disorder and provide context for regulatory submissions and approvals of complement inhibitors such as YARTEMLEA and OMS1029.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important elements of lengthy filings, helping readers quickly locate information on topics such as major transactions, clinical and regulatory milestones, and shareholder votes. Real-time updates from EDGAR ensure that new OMER 8-Ks, 10-Qs, 10-Ks, and Form 4 insider transaction reports become available on this page as they are filed, while the AI layer explains complex language and structures in more accessible terms.
Omeros Corporation (OMER) – Form 4 filing dated 07/01/2025
Non-employee director Dr. Peter A. Demopulos was automatically granted a stock option for 15,000 common shares under the company’s director compensation policy following the annual shareholder meeting on 06/27/2025. The option’s key terms are:
- Exercise price: $3.20 per share
- Expiration: 06/27/2035 (10-year tenor)
- Vesting: fully vests the day before the 2026 annual meeting, contingent on continued board service
- Ownership designation: direct (D); post-grant derivative holdings reported at 15,000 options
The filing reflects routine annual equity compensation for board members and does not disclose any open-market purchases or sales of common shares.